Background♦ Remdesivir (RDV) reduced time to recovery and improved clinical outcomes
for COVID-19 patients in several randomized controlled trials1, 2; with additional evidence …

We would like to share ideas on the publication “Early Use of Remdesivir in Patients
Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational …

Purpose The benefits of antiviral treatment with remdesivir in hospitalized patients with
COVID-19 remain controversial. Clinical analyses are needed to demonstrate which patient …

We thank Beccacece et al. for their letter to the editor notifying that a study that we included
in our recent meta-analysis has since been retracted. We believe that it is paramount to …

Background Immunocompromised patients are at high risk of severe coronavirus disease
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …

Remdesivir is approved for the treatment of hospitalized coronavirus disease 2019 (COVID-
19) patients. 1 Up to 5%–10% of discharged COVID-19 patients require readmission, most …

In their Letter to the Editor “Remdesivir for COVID-19: Why Not Dose Higher?” Yan and
Muller assert that the clinical efficacy of remdesivir at its currently approved dose (200 mg …

Background The use of remdesivir has demonstrated a significant reduction in the time to
recovery in patients with COVID-19. However, the impact on mortality is still controversial …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of SARS-CoV-2. Methods This was a retrospective comparative …

Background Remdesivir is approved by the US Food and Drug Administration for the
treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been …